Healthcare law company Frier Levitt has analyzed FDA enforcement actions in opposition to “investigate only” peptide vendors. Their conclusion: the FDA considers an item’s classification according to its intended use, not its disclaimers. When Internet sites incorporate dosage guides, reconstitution